| Jones, Robert |
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Vemurafenib, Zelboraf, Cobimetinib, Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic | 10/29 | 10/29 | | |
DETERMINE, NCT05722886: (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol |
|
|
| Recruiting | 2/3 | 825 | Europe | Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy | 10/29 | 10/29 | | |
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations |
|
|
| Recruiting | 2/3 | 30 | Europe | Trastuzumab, Herceptin, Pertuzumab, Perjeta | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm | 10/29 | 10/29 | | |
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition |
|
|
| Recruiting | 2/3 | 30 | Europe | Atezolizumab, Tecentriq | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers |
|
|
| Recruiting | 2/3 | 30 | Europe | Alectinib, Alecensa | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Entrectinib, Rozlytrek | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma | 10/29 | 10/29 | | |
| Recruiting | 2 | 332 | Europe, Canada, Japan, US, RoW | disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 10/24 | 03/26 | | |
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer |
|
|
| Active, not recruiting | 1b/2 | 149 | Europe | AZD5363, Placebo, Fulvestrant | Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board | Estrogen Receptor Positive Breast Cancer | 03/19 | 12/23 | | |
|
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 150 | Europe | HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion | Cancer Research UK, Heptares Therapeutics Limited | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas | 09/26 | 09/26 | | |
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study |
|
|
| Terminated | N/A | 34 | US | ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing | DePuy Orthopaedics | Osteoarthritis of the Knee | 03/23 | 03/23 | | |
| Active, not recruiting | N/A | 357 | Europe, Canada, US, RoW | Merit WRAPSODY Endovascular Stent Graft, PTA | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 02/24 | 01/26 | | |
NCT05527483: Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients |
|
|
| Completed | N/A | 32 | US | [68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT | University Hospitals Cleveland Medical Center | Prostate Cancer | 10/22 | 10/22 | | |
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda |
|
|
| Recruiting | N/A | 5600 | RoW | Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc | Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED | Malaria, Mosquito-Borne Disease | 09/25 | 09/25 | | |
NCT04682665: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases |
|
|
| Recruiting | N/A | 250 | Europe | Icosapent Ethyl Oral Capsule, Placebo | University of Leeds, National Cancer Institute (NCI), Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard School of Public Health (HSPH), University of Bradford | Colon Cancer Liver Metastasis | 07/24 | 07/25 | | |
| Recruiting | N/A | 500 | Europe, RoW | Merit WRAPSODY Endovascular Stent Graft | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 09/24 | 09/26 | | |
| Recruiting | N/A | 6000 | Europe | | The Christie NHS Foundation Trust | Cancer | 01/26 | 01/28 | | |
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry |
|
|
| Recruiting | N/A | 614 | Europe | GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) | W.L.Gore & Associates | Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury | 10/26 | 10/35 | | |
ACTRN12619000470190: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study |
|
|
| Not yet recruiting | N/A | 100 | | | University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund | Liver Transplantation
, Anaesthetics | | | | |
ACTRN12619000470190p: FLASH.V: Flash Glucose Monitoring and Surgery in the Hepatopancreaticobiliary (HPB) Surgery and Liver Transplant Population - Verification Study |
|
|
| Not yet recruiting | N/A | 100 | | | University of Melbourne: Department of Surgery , Austin Health Liver Transplant Unit, Austin Medical Research Fund | Liver Transplantation
; Anaesthetics | | | | |
| Recruiting | N/A | 2000 | Europe | Biosampling | University of Liverpool, Countess of Chester NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, Clatterbridge Centre for Oncology, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool Womens Hospital | Cancer, Surgery | 01/30 | 01/30 | | |
| Connelly, Diana |
EXPEDE, NCT04081103: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries |
|
|
| Recruiting | 2 | 108 | US | Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Placebo, Open-label Nexagon® (lufepirsen) | Amber Ophthalmics, Inc. | Corneal Persistent Epithelial Defect | 03/23 | 03/23 | | |
NCT03970525: Venturi and Peristaltic Based Phacoemulsification in Femtosecond Laser Cataract Surgery |
|
|
| Completed | N/A | 111 | US | Venturi pump, Peristaltic vacuum pump | Wendell Scott, Johnson & Johnson Surgical Vision, Inc. | Cataract Senile | 03/23 | 03/23 | | |
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study |
|
|
| Terminated | N/A | 34 | US | ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing | DePuy Orthopaedics | Osteoarthritis of the Knee | 03/23 | 03/23 | | |
